- Previous Close
698.00 - Open
700.00 - Bid 692.00 x --
- Ask 693.00 x --
- Day's Range
681.00 - 700.00 - 52 Week Range
673.00 - 975.00 - Volume
823,764 - Avg. Volume
1,386,121 - Market Cap (intraday)
71.41B - Beta (5Y Monthly) 0.66
- PE Ratio (TTM)
19.30 - EPS (TTM)
35.85 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield 12.00 (1.73%)
- Ex-Dividend Date Aug 12, 2024
- 1y Target Est
978.67
Bora Pharmaceuticals Co., LTD. researches and develops, manufactures, distributes, and sells pharmaceuticals worldwide. The company operates through Sales, Contract Development & Manufacturing Organization, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services, including clinical and commercial manufacturing, pharmaceutical development, packaging and serialization, analytical and microbiology testing, and regulatory affairs services. In addition, it provides food and vitamin supplements, and skincare products; and biotechnical services. The company sells its products directly to clinics, pharmacies, pharmacy chains, and drug stores, as well as through distributors to medical centers, corporate and public hospitals, and regional and district hospitals. Bora Pharmaceuticals Co., LTD. was incorporated in 2007 and is based in Taipei City, Taiwan.
www.bora-corp.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 6472.TW
View MorePerformance Overview: 6472.TW
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6472.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6472.TW
View MoreValuation Measures
Market Cap
71.41B
Enterprise Value
84.47B
Trailing P/E
19.32
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.03
Price/Book (mrq)
5.55
Enterprise Value/Revenue
4.39
Enterprise Value/EBITDA
13.07
Financial Highlights
Profitability and Income Statement
Profit Margin
20.47%
Return on Assets (ttm)
5.98%
Return on Equity (ttm)
30.18%
Revenue (ttm)
19.25B
Net Income Avi to Common (ttm)
3.94B
Diluted EPS (ttm)
35.85
Balance Sheet and Cash Flow
Total Cash (mrq)
5.92B
Total Debt/Equity (mrq)
126.39%
Levered Free Cash Flow (ttm)
-4.97B